Patents by Inventor Ramakrishnan Melarkode

Ramakrishnan Melarkode has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
    Publication number: 20240101700
    Abstract: The present invention discloses a key mechanism of action of itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 28, 2024
    Inventors: Pradip NAIR, Arindam SAHA, Ravindra Belavinakodige SADASHIVARAO, Usha BUGHANI, Ramakrishnan MELARKODE
  • MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUS
    Publication number: 20220227880
    Abstract: The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).
    Type: Application
    Filed: December 22, 2021
    Publication date: July 21, 2022
    Inventors: Pradip NAIR, Ravindra Belavinakodige SADASHIVARAO, Ramakrishnan MELARKODE
  • Method for detecting neutralizing antibodies against recombinant human insulin in human serum
    Patent number: 11340238
    Abstract: The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: May 24, 2022
    Assignee: BIOCON LIMITED
    Inventors: Abhishek Kulshrestha, Ravi Shankar Maurya, Sudeep Sabde, Pallavi Hajela, Pawan Kalani, Ramakrishnan Melarkode, Narendra Chirmule
  • Monoclonal antibody and a method of use for the treatment of lupus
    Patent number: 11242401
    Abstract: The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 8, 2022
    Inventors: Pradip Nair, Ravindra Belavinakodige Sadashivarao, Ramakrishnan Melarkode
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20220025038
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 27, 2022
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • Use of a CD6 binding partner and method based thereon
    Patent number: 11028168
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 8, 2021
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20210122829
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: April 29, 2020
    Publication date: April 29, 2021
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
  • Monoclonal antibody and a method thereof
    Patent number: 10669346
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 2, 2020
    Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20190345247
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 14, 2019
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
    Publication number: 20190248913
    Abstract: The present invention discloses a key mechanism of action of Itolizumab that involves a decrease in an activating ALCAM-CD6 co stimulatory signal by directly reducing CD6 hyperphosphorylation and preventing the docking of key molecules associated with T cell activation and signaling.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 15, 2019
    Inventors: Pradip NAIR, Arindam SAHA, Ravindra Belavinakodige SADASHIVARAO, Usha BUGHANI, Ramakrishnan MELARKODE
  • A MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUS
    Publication number: 20190241670
    Abstract: The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).
    Type: Application
    Filed: October 17, 2017
    Publication date: August 8, 2019
    Applicant: Biocon Limited
    Inventors: Pradip NAIR, Ravindra Belavinakodige SADASHIVARAO, Ramakrishnan MELARKODE
  • Methods for controlling fucosylation levels in proteins
    Patent number: 10308970
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 4, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Rasika Venkataraman, Laxmi Adhikary, Ankur Bhatnagar, Sunaina Prabhu, Kriti Shukla, Dinesh Baskar, Saravanan Desan, Harish Venkatraman Pai, Jose Enrique Montero Casimiro
  • Use of a CD6 binding partner and method based thereon
    Patent number: 10189899
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 29, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • METHOD FOR DETECTING NEUTRALIZING ANTIBODIES AGAINST RECOMBINANT HUMAN INSULIN IN HUMAN SERUM
    Publication number: 20180306814
    Abstract: The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.
    Type: Application
    Filed: October 15, 2016
    Publication date: October 25, 2018
    Inventors: Abhishek KULSHRESTHA, Ravi Shankar MAURYA, Sudeep SABDE, Pallavi HAJELA, Pawan KALANI, Ramakrishnan MELARKODE, Narendra CHIRMULE
  • A MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20180258179
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
  • Monoclonal antibody and a method thereof
    Patent number: 10000573
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 19, 2018
    Assignees: CENTRO DE IMMUNOLOGIA MOLECULAR, BIOCON LIMITED
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • METHODS FOR CONTROLLING FUCOSYLATION LEVELS IN PROTEINS
    Publication number: 20180087080
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 29, 2018
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, RASIKA VENKATARAMAN, LAXMI ADHIKARY, ANKUR BHATNAGAR, SUNAINA PRABHU, KRITI SHUKLA, DINESH BASKAR, SARAVANAN DESAN, HARISH VENKATRAMAN PAI, JOSE ENRIQUE MONTERO CASIMIRO
  • Methods for controlling fucosylation levels in proteins
    Patent number: 9856502
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 2, 2018
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Rasika Venkataraman, Laxmi Adhikary, Ankur Bhatnagar, Sunaina Prabhu, Kriti Shukla, Dinesh Baskar, Saravanan Desan, Harish Venkatraman Pai, Jose Enrique Montero Casimiro
  • MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20170281808
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: May 31, 2017
    Publication date: October 5, 2017
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
  • Monoclonal antibody and a method thereof
    Patent number: 9670285
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 6, 2017
    Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez